This cohort included 15 additional soft tissue sarcomas with complex rearrangements between YAP1 and KMT2A (Table 1), two soft tissue sarcomas with VIM–KMT2A (Supplementary Table 2, patients #S1–S2), and 16 soft tissue sarcomas with KMT2A fusions to unique non-YAP1 non-VIM partners (Supplementary Table 2, patients #S3–S18). This evidence concerns the gene KMT2A and soft tissue sarcoma.